Biomarkers for the response to immunotherapy in patients with non-small cell lung cancer

Author(s):
Muller, M.
Published
2024
Publication type
Doctoral Thesis

Abstract

Lung cancer is the leading cause of cancer death in the Netherlands. For years chemotherapy was the only (palliative) treatment, with a short survival of only months. Since the introduction of immunotherapy in 2015, this survival has increased significantly, with the first results showing a survival of even a few years. However, the response rate is relatively low, the treatment is expensive and the (low percentage of) side effects are severe. Therefore a biomarker is needed to predict which patients would benefit of immunotherapy.

This thesis is about the search for a new biomarker. With the use of the RNA of platelets, proteins, tumor markers in blood and a an electronic nose for exhaled breath, we tried to find a non-invasive biomarker for the prediction of response on immunotherapy and for the (future) use in clinical practice, some of which are promising.

ImmunotherapyCheckpoint inhibitorBiomarkerTumor markerPlatelet RNAExhaled breathProteinModelingResponse monitoringResponse prediction
Defense date
2024-05-29
Language
English
Supervisor(s)
Baas, P.; Heuvel, M.M. van den
Advisor(s)
Rossum, H.H. van
Committee member(s)
Neefjes, J.J.C.; Smit, E.F.; Borst, J.G.; Maitland- van der Zee, A.H.; Würdinger, T.
Qualification
Ph.D.
Degree granting institution
Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden
hdl
1887/3754842
ISBN(s)
9789493330863

Funding

Sponsorship
Financial support for printing of this thesis was kindly provided by the Oncology Graduate School Amsterdam (OOA) and university of Leiden.